FindTrial
Sign In

Acute Kidney injury in patients undergoing Cytoreductive surgery and HIPEC

Incidence and predictors of Acute Kidney Injury following Cytoreductive Surgery- Hyperthermic Intraperitoneal Chemotherapy : a retrospective study - NIL

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
CTRI
Registry ID
CTRI/2026/04/108580
Enrollment
60
Registered
2026-04-17
Start date
Unknown
Completion date
Unknown
Last updated
2026-04-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: N17-N19- Acute kidney failure and chronic kidney disease

Interventions

Intervention1: Nil: Nil Intervention2: Nil: Nil Intervention3: Nil: Nil

Sponsors

Malabar Cancer Centre
Lead Sponsor

Eligibility

Inclusion criteria

Inclusion criteria: All patients undergoing Cytoreductive Surgery- Hyperthermic Intraperitoneal Chemotherapy from January 2018 to December 2024

Exclusion criteria

Exclusion criteria: Patients with incomplete data

Design outcomes

Primary

MeasureTime frame
To determine the incidence of Acute Kidney Injury in patients undergoing Cytoreductive Surgery - Hyperthermic Intraperitoneal ChemotherapyTimepoint: Postoperative AKI in First seven postoperative days—

Secondary

MeasureTime frame
To study the factors associated with Acute Kidney InjuryTimepoint: Postoperative AKI will be noted in the first seven postoperative days;To detect the incidence of Chronic Kidney Disease in patients who developed Acute Kidney InjuryTimepoint: CKD will be evaluated atleast 3 months after surgery—

Countries

India

Contacts

Public ContactNamratha Divakaran

Malabar Cancer Centre

namrathadivakaran@gmail.com9445114315

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: May 1, 2026